Elotuzumab
- Generic Name
- Elotuzumab
- Brand Names
- Empliciti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 915296-00-3
- Unique Ingredient Identifier
- 1351PE5UGS
- Background
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. ...
- Indication
Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
- Associated Conditions
- Refractory Multiple Myeloma
- Associated Therapies
- -
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 53
- Registration Number
- NCT04835129
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
FT538 in Subjects With Advanced Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 42
- Registration Number
- NCT04614636
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Natalie Callendar
- Registration Number
- NCT04584307
Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT04517851
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
- Conditions
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 424
- Registration Number
- NCT03989414
- Locations
- 🇺🇸
Local Institution - 110, Winston-Salem, North Carolina, United States
🇨🇿Local Institution - 802, Brno, Czechia
🇨🇿Local Institution - 801, Ostrava-Poruba, Czechia
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
- Conditions
- Interventions
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Wuerzburg University Hospital
- Target Recruit Count
- 576
- Registration Number
- NCT03948035
- Locations
- 🇩🇪
Universitätsklinikum Ulm, Ulm, Baden-Wuerttemberg, Germany
🇩🇪Vivantes Klinikum Spandau, Berlin, Germany
🇩🇪Universitätsklinikum Münster, Münster, North Rhine-Westphalia, Germany
Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 41
- Registration Number
- NCT03713294
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 381
- Registration Number
- NCT03651128
- Locations
- 🇺🇸
Local Institution - 145, Los Angeles, California, United States
🇺🇸Local Institution - 122, Los Angeles, California, United States
🇺🇸Local Institution - 131, Atlanta, Georgia, United States
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2023-03-29
- Target Recruit Count
- 18
- Registration Number
- NCT03411031
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Registration Number
- NCT03393273
- Locations
- 🇫🇷
Hématologie et thérapie cellulaire, Hôpital Saint Antoine, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.